BRAF and melanoma: Following the introduction of CTLA4 and PD1 immune checkpoint inhibitors, the optimal sequence of targeted therapy and immunotherapy for the treatment of patients with BRAF-mut melanoma is under investigation in clinical trials (DREAMseq [NCT02224781] and SECOMBIT [NCT02631447]).